Stratification of Patients using advanced Integrative modeling of Data Routinely acquired for diagnosing Rheumatic complaints

HealthHORIZON-RIAID: 101080711
EC Contribution
€51,830
Consortium Size
25 orgs
Start Year
2023
β–ΆSummary

Globally 1.Globally 1.71 billion people have musculoskeletal symptoms, the leading contributor to disability. Early disease stratification is important to ensure appropriate care (most suited healthcare provider and best treatment choice). Currently the patient journey to diagnosis and effective treatment is long and inefficient, resulting in persistent disease burden and economical loss. This is due to insufficiently understood relations disease causes and similarities in symptoms between diseases, insufficiently distinguishing tests, trial and error approach in initial treatment.SPIDeRR aims to disentangle the real-life complexity of early diagnosis of rheumatic diseases by considering the complete web of factors influencing patients’ symptoms. SPIDeRR’s approach will go well beyond the state-of-the-art in the following ways:- By identifying different disease groups, requiring different therapies, amongst patients with similar symptoms in contrast to the traditional approach aiming to only capture one disease early. - By integrating all relevant data dimensions from every healthcare level (primary and secondary care and patients seeking advice online). - By translating and applying machine learning techniques from the β€œomics” field to clinical patient data, which will result in new pipelines for translational data science SPIDERR will deliver three clinical models -a symptom checker for patients -a decision support tool for (primary) care providers providing guiding additional examination and referral decisions-a patient-patient similarity network to optimise diagnostic groups in rheumatology and support treatment decisionTo achieve this we additionally deliver solutions for data integration and shared analyses though GDPR compliant digital research environment and federated learning pipelines.Finally we will test the acceptability of the models through stakeholders studies and provide an implementation scene tailored to current healthcare in Europe.

Consortium (25)

πŸ‡³πŸ‡± ACADEMISCH ZIEKENHUIS LEIDENNL
coordinator
πŸ‡ΈπŸ‡ͺ ELSA SCIENCE ABSE
partner
πŸ‡³πŸ‡± ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAMNL
partner
πŸ‡©πŸ‡ͺ FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERGDE
partner
πŸ‡ͺπŸ‡Έ FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL GREGORIO MARANONES
partner
πŸ‡ͺπŸ‡Έ FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSIATRIO LA PAZES
partner
πŸ‡ͺπŸ‡Έ FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO 12 DE OCTUBREES
partner
πŸ‡ͺπŸ‡Έ FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO CLINICO SAN CARLOSES
partner
πŸ‡ͺπŸ‡Έ FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO LA PRINCESAES
partner
πŸ‡ͺπŸ‡Έ FUNDACION PARA LA INVESTIGACION E INNOVACION BIOSANITARIA DE ATENCION PRIMARIAES
partner
πŸ‡¬πŸ‡· IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINONGR
partner
πŸ‡ͺπŸ‡Έ INSTITUTO DE SALUD MUSCULOESQUELETICA SLES
partner
πŸ‡³πŸ‡± IQVIA SOLUTIONS B.V.NL
partner
πŸ‡ΈπŸ‡ͺ KAROLINSKA INSTITUTETSE
partner
πŸ‡©πŸ‡ͺ MEDIZINISCHE HOCHSCHULE BRANDENBURG CAMPUS GMBHDE
partner
πŸ‡©πŸ‡ͺ PHADIA GMBHDE
partner
πŸ‡©πŸ‡ͺ PHILIPPS UNIVERSITAET MARBURGDE
partner
πŸ‡­πŸ‡Ί SEMMELWEIS EGYETEMHU
partner
πŸ‡ͺπŸ‡Έ SERVICIO MADRILENO DE SALUDES
partner
πŸ‡³πŸ‡± Stichting ReumaNederlandNL
partner
TECHNISCHE UNIVERSITEIT DELFT
partner
πŸ‡¬πŸ‡§ THE ACADEMIC HEALTH SCIENCE NETWORK FOR THE NORTH EAST AND NORTH CUMBRIA LIMITEDGB
partner
πŸ‡¬πŸ‡§ THE UNIVERSITY OF MANCHESTERGB
partner
πŸ‡©πŸ‡ͺ UNIVERSITATSKLINIKUM ERLANGENDE
partner
πŸ‡¬πŸ‡§ UNIVERSITY OF NEWCASTLE UPON TYNEGB
partner